GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
Subscribe To Our Newsletter & Stay Updated
